This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Lymphoma
and you are
over 18
years old
Phase
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

RATIONALE: Immunotoxins such as denileukin diftitox can locate cancer cells and kill them without harming normal cells. This may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of denileukin diftitox in treating patients who have non-Hodgkin's lymphoma that has not responded to previous treatment.

Provided treatments

  • Biological: denileukin diftitox
Tris trial is registered with FDA with number: NCT00003615. The sponsor of the trial is Eastern Cooperative Oncology Group and it is looking for 77 volunteers for the current phase.
Official trial title:
A Phase II Study of DAB 389 IL-2, an Interleukin-2 Fusion Toxin, for Previously Treated Stage II, III, and IV Follicular Low-Grade Non-Hodgkin's Lymphoma